Boronophenylalanine‐Containing Polydopamine Nanoparticles for Enhanced Combined Boron Neutron Capture Therapy and Photothermal Therapy for Melanoma Treatment

Liqun Dai,Tao Wang,Siming Zhou,Lili Pan,Yi Lu,Tingyu Yang,Wentao Wang,Zhiyong Qian

DOI: https://doi.org/10.1002/adfm.202402893

IF: 19

2024-05-02

Advanced Functional Materials

Abstract:Boronophenylalanine‐containing polydopaine (B‐PDA) nanoparticles, synthesized through the encapsulation of boronophenylalanine in polydopamine, integrate boron neutron capture therapy (BNCT) with photothermal therapy (PTT) for melanoma. Targeting the overexpressed neutral amino acid transporter 1 (LAT1) in melanoma cells, they induce localized heating and enhance sensitivity to BNCT, offering a promising strategy for melanoma treatment. Melanoma, the most aggressive skin cancer type, is challenging to treat due to its high metastatic potential and low response to conventional therapies. Innovative approaches, including combination therapies, are crucial for enhancing treatment efficacy while minimizing side effects. It is developed boronophenylalanine‐containing polydopaine (B‐PDA) nanoparticles by encapsulating boronophenylalanine in polydopamine through nitrogen‐boronate coordination, targeting both boron neutron capture therapy (BNCT) and photothermal therapy (PTT). With stability and biocompatibility under physiological conditions, these nanoparticles utilize the phenylalanine residues in BPA to target the overexpressed neutral amino acid transporter 1 (LAT1) in melanoma cells, resulting in enhanced cell‐specific targeting. B‐PDA nanoparticles demonstrated significant photothermal effects under external stimulation, inducing localized heating and triggering heterogeneous tumor cell death, thereby enhancing sensitivity to BNCT. Combining BNCT and PTT, the B‐PDA nanoparticles offer a promising strategy for melanoma treatment.

materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology